Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
This randomized clinical trial investigates the effects of solanezumab and ganterenumab on downstream biomarkers in individuals with dominantly inherited Alzheimer disease.